Category Archives: Cell Therapy

Autologous cell therapy is now being used to help with avascular necrosis at the Center for Regenerative Medicine, according to Dr. Farshchian. Miami, Fl (PRWEB) December 10, 2012 Avascular necrosis can be quite devastating, and lead to total loss of the ankle joint with arthritis, deformity and pain. Loss of blood supply to the bone can be caused by an injury (trauma-related avascular necrosis) When a joint is injured, as in a fracture or dislocation, the blood vessels may be damaged. This can interfere with the blood circulation to the bone and lead to trauma-related avascular necrosis. Studies suggest that this type of avascular necrosis may develop in more than 20 percent of people who dislocate their hip joint. Some medicines such as Corticosteroids are commonly used to treat diseases in which there is inflammation, such as systemic lupus erythematosus, rheumatoid arthritis, and vasculitis. Studies suggest that long-term, systemic (oral or intravenous) corticosteroid use is associated with 1/3 of all cases of non-traumatic avascular necrosis. The current theory is corticosteroids may interfere with the body's ability to break down fatty substances. These substances then build up in and clog the blood vessels, causing them to narrow. This makes less blood … Continue reading →

"Cell therapy is now being used for carpal tunnel syndrome at the Center for Regenerative Medicine." According to Dr. Farshchian. (PRWEB) December 11, 2012 "Current studies seem to be very impressive with use of regenerative medicine in orthopedic problems," A.J. Farshchian MD From the Center for Regenerative Medicine said earlier in a discussion on arthritis and sports injuries. Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites. Carpal tunnel syndrome occurs when the median nerve, which runs from the forearm into the hand, becomes pressed or squeezed at the wrist. The median nerve controls sensations to the palm side of the thumb and fingers except for the fifth digit or also known as little finger. The median nerve also carries impulses to some small muscles in the hand that allow the … Continue reading →

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- The Global Institute Of Stem-cell Therapy And Research (GIOSTAR) announced today a collaborative treatment plan to serve the local population suffering from a genetic disease, Sickle Cell Anemia. President and CEO, Mr. Deven Patel and his team met with Honorable Chief Minister Shri Arjun Munda of State of Jharkhand, India in November 2012 to address the local population's medical needs. A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16184. As a follow-up, a government delegation representing the state of Jharkhand, India; Chief Minister, Principal Health Secretary, Chief Secretary and many other officials are visiting GIOSTAR in San Diego on December 14, 2012 to finalize the proposed two (2) billion U.S. dollar contract to be serviced over the next 15 years. Bob Filner, Mayor of San Diego and City Council Members are among the invited guests for this state visit along with representatives from Belize and the island nation of Saint Vincent and the Grenadines. Two hundred (200) jobs are estimated to be created in San Diego and it is expected that the dialog would include an economic development program between City of San Diego and State of Jharkhand, India. GIOSTAR is a … Continue reading →

Emily Whitehead First Child Treated in Trial of T Cell Therapy for Acute Lymphoblastic Leukemia In April 2012, 7-year-old cancer patient Emily (Emma) Whitehead became the first child to be enrolled in CTL019, a clinical trial for patients with B cell cancers such as acute lymphocytic leukemia (ALL), B cell non-Hodgkin lymphoma (NHL), and the adult disease chronic lymphocytic leukemia (CLL). Emily received this experimental treatment at The Children's Hospital of Philadelphia in April 2012 after her cancer relapsed for the second time. Her cancer has been in remission since her treatment.From:ChildrensHospPhilaViews:6 0ratingsTime:06:45More inScience Technology See the article here: Emily Whitehead First Child Treated in Trial of T Cell Therapy for Acute Lymphoblastic Leukemia - Video … Continue reading →

Alan Fine on Advances in stem cell therapy Alan Fine, Professor of Medicine, Director Stem Cell Biology Program, Boston University Alan Fine spoke at the Expert Exchange Roundtable on Pushing the boundaries of longevity, 9 September 2011, sSwissnex Boston, Cambridge, Massachusetts, USAFrom:swissretvViews:0 0ratingsTime:01:18:35More inEducation Read more here: Alan Fine on Advances in stem cell therapy - Video … Continue reading →

Live Cell Therapy | Stem Cell Malaysia stemcellmalaysia.com Live cell therapy is one form of stem cell therapy under the hierarchy of cell therapy, which is under regenerative medicine. Live cell therapy was made popular since 1931 by Dr Paul Niehans, who pioneered the therapy using injection. Oral or injection live cell therapy is far more superior than surgical implantation due to several advantages. Today, live cell therapy has been applied to disease treatment, beauty and health rejuvenation. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:172 10ratingsTime:12:14More inScience Technology Read more: Live Cell Therapy | Stem Cell Malaysia - Video … Continue reading →

Live Cell Therapy | Stem Cell Malaysia stemcellmalaysia.com Live cell therapy is one form of stem cell therapy under the hierarchy of cell therapy, which is under regenerative medicine. Live cell therapy was made popular since 1931 by Dr Paul Niehans, who pioneered the therapy using injection. Oral or injection live cell therapy is far more superior than surgical implantation due to several advantages. Today, live cell therapy has been applied to disease treatment, beauty and health rejuvenation. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:172 10ratingsTime:12:14More inScience Technology Read more: Live Cell Therapy | Stem Cell Malaysia - Video … Continue reading →

Zell-V Cell Therapy - Best Anti Aging Product http://www.zell-v.comFrom:zellvsheepplacentaViews:0 0ratingsTime:02:16More inHowto Style Read the original post: Zell-V Cell Therapy - Best Anti Aging Product - Video … Continue reading →

SILVER SPRING, Md., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today its subsidiary Austrianova Singapore (ASPL) has published a new manuscript that describes the use of the Company's proprietary cell encapsulation technology for studies designed to create a cell based therapeutic treatment for diabetes. The publication in the Wiener Medizinische Wochenschrift Skriptum, entitled "Cell encapsulation for the treatment of diabetes" was co-authored with Dr. Eva Brandtner, former ASPL Chief Scientific Officer who is presently at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Austria. The manuscript outlines the advantages of using cellulose sulfate for the encapsulation of cells for treatment of diabetes. The article accompanied an invited presentation on the same topic at the Diabetes Meeting in Salzburg, Austria also given by Dr. Brandtner. ASPL and VIVIT have planned and are working closely together to advance and develop the diabetes treatment using encapsulated cells capable of expressing insulin after they detect the presence of glucose. Ultimately, the aim is to place insulin-secreting cells encapsulated in cellulose sulphate in patients with diabetes to replace the patient's own cells that no longer secrete insulin in response to … Continue reading →

GAITHERSBURG, MD--(Marketwire - Dec 6, 2012) - Cytomedix, Inc. ( OTCQX : CMXI ) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today the signing of an agreement with NIH to collaborate on a Phase 2 clinical study in patients with intermittent claudication (IC).IC is caused by peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles of the leg. The study is being funded by NHLBI/NIH and managed by the Cardiovascular Cell Therapy Research Network (CCTRN), which is also responsible for enrolling patients. The CCTRN is a network that includes seven centers in the United States with experience and expertise in stem cell clinical trials studying treatments for cardiovascular heart diseases. The Phase 2 PACE (Patients with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.The primary endpoints of the study are safety and the change in peak walking time at 6 months compared to baseline.Additionally, changes in leg collateral arterial anatomy, calf muscle blood flow, and tissue perfusion as determined by … Continue reading →